International Clinical Psychopharmacology

2.5(top 20%)

impact factor

3.4K(top 5%)

papers

71.8K(top 5%)

citations

108(top 5%)

h-index

2.7(top 20%)

impact factor

3.6K

all documents

74.4K

doc citations

158(top 5%)

g-index

Top Articles

#	Title	Journal	Year	Citations
1	The measurement of disability	International Clinical Psychopharmacology	1996	1,159
2	Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)	International Clinical Psychopharmacology	1994	418
3	Depression in the community	International Clinical Psychopharmacology	1997	413
4	Anxiety and the Anxiety Disorders	International Clinical Psychopharmacology	1990	396
5	A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder	International Clinical Psychopharmacology	2012	375
6	Efficacy of treatments for anxiety disorders	International Clinical Psychopharmacology	2015	369
7	Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study	International Clinical Psychopharmacology	2002	323
8	A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500)	International Clinical Psychopharmacology	2002	322
9	Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale	International Clinical Psychopharmacology	2008	319
10	Antioxidant enzyme activities and oxidative stress in affective disorders	International Clinical Psychopharmacology	2004	301
11	The social and economic burden of treatment-resistant schizophrenia	International Clinical Psychopharmacology	2014	289
12	Biological rhythm disturbances in mood disorders	International Clinical Psychopharmacology	2006	279
13	Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial	International Clinical Psychopharmacology	2007	268
14	Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale	International Clinical Psychopharmacology	1995	263
15	Imputing response rates from means and standard deviations in meta-analyses	International Clinical Psychopharmacology	2005	261
16	A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia	International Clinical Psychopharmacology	1994	256
17	Effect of a Serotonin and Noradrenaline Uptake Inhibitor in Panic Disorder; a Double-blind Comparative Study with Fluvoxamine and Maprotiline	International Clinical Psychopharmacology	1988	242
18	A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables	International Clinical Psychopharmacology	1995	242
19	Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey	International Clinical Psychopharmacology	2000	234
20	The GRID-HAMD: standardization of the Hamilton Depression Rating Scale	International Clinical Psychopharmacology	2008	232
21	Pharmacology and pharmacokinetics of milnacipran	International Clinical Psychopharmacology	2002	228
22	Selective serotonin reuptake inhibitors	International Clinical Psychopharmacology	1994	227
23	Depot neuroleptics in relapse prevention	International Clinical Psychopharmacology	1995	217
24	Sexual problems in healthy and depressed persons	International Clinical Psychopharmacology	1998	217
25	Equivalence of St Johnʼs wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mildmoderate depression	International Clinical Psychopharmacology	2000	210
26	A Comparison of Fluoxetine Imipramine and Placebo in Patients with Bipolar Depressive Disorder	International Clinical Psychopharmacology	1989	208
27	A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder	International Clinical Psychopharmacology	2008	205
28	Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study	International Clinical Psychopharmacology	2006	199
29	A comparative review of escitalopram, paroxetine, and sertraline	International Clinical Psychopharmacology	2014	198
30	Impulsive aggression and central serotonergic system function in humans	International Clinical Psychopharmacology	1992	197
31	Escitalopram 10???mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care	International Clinical Psychopharmacology	2002	197
32	Predictors of an acute antidepressant response to fluoxetine and sertraline	International Clinical Psychopharmacology	1999	196
33	Trihexyphenidyl (Artane) abuse in schizophrenic patients	International Clinical Psychopharmacology	1996	191
34	SPRINT: a brief global assessment of post-traumatic stress disorder	International Clinical Psychopharmacology	2001	186
35	The neuropharmacology of serotonin and noradrenaline in depression	International Clinical Psychopharmacology	2002	185
36	Tolerability of paliperidone: a meta-analysis of randomized, controlled trials	International Clinical Psychopharmacology	2010	184
37	Guideline for the Dosage of Neuroleptics. I	International Clinical Psychopharmacology	1989	181
38	D-cycloserine does not enhance exposure–response prevention therapy in obsessive–compulsive disorder	International Clinical Psychopharmacology	2007	179
39	Dose correspondence between olanzapine long-acting injection and oral olanzapine	International Clinical Psychopharmacology	2011	178
40	Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer??s disease	International Clinical Psychopharmacology	2003	177
41	The mesolimbic dopamine system as a target for rapid antidepressant action	International Clinical Psychopharmacology	1997	175
42	The use of lorazepam TID for chronic insomnia	International Clinical Psychopharmacology	1999	175
43	The effects of D- and L-fenfluramine (and their interactions with D-amphetamine) on psychomotor function and mood	International Clinical Psychopharmacology	1996	174
44	Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study	International Clinical Psychopharmacology	2004	174
45	The role of serotonin in depression and anxiety	International Clinical Psychopharmacology	1995	172
46	The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission	International Clinical Psychopharmacology	1995	170
47	Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder	International Clinical Psychopharmacology	2019	170
48	Safety of mirtazapine: a review	International Clinical Psychopharmacology	1995	169
49	Clinical utility of milnacipran in comparison with other antidepressants	International Clinical Psychopharmacology	2002	169
50	Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks	International Clinical Psychopharmacology	1995	168

Scientometrics

Overviews

Citing Bodies

International Clinical Psychopharmacology

Top Articles